MPXX is the proprietor of the patented MPXX™ technology
MPXX™ technology cuts allergenic proteins, allergens & chemical residues from Natural Rubber Latex & synthetic rubber products to unquantifiable & undetectable levels. Hence, it enables maximum protection & ultimate prevention by drastically diminishing the risk of type I and IV allergies.
Our passion & expertise date back to 1995, when the founder of the Dutch R & D company BUDEV, strongly aware of the importance of the growing latex allergy & occupational safety issues, initiated the research & development of MPXX™. In co-operation with scientific partner-organizations such as the Erasmus University Medical Centre in Rotterdam & the Malaysian Rubber Board, Budev BV developed and patented different technologies, including MPXX™.
The objective was to implement MPXX™ technology worldwide with selected dynamic partners who had an excellent track-record in quality & efficiency within the medical and industrial sector & opted to apply the MPXX™ technology first on medical gloves.
In 2015 we changed our name to MPXX, matching it with our technology which represents the core of our business and key to our success.
To maximize the reach & the benefits of the revolutionary MPXX™ technology, we are executing R&D for the application, feasibility & implementation of the patented MPXX™ technology on other natural rubber or synthetic rubber products.
MPXX is obsessed with quality: products treated with the MPXX™ technology exceed international standards and are constantly subjected to different types of tests executed by worldwide accredited laboratories.
With superior products, corporate responsibility and strong values MPXX is proud to offer unique solutions for health, safety and well-being.